Biography
Arie S. Belldegrun is a trail blazing urologic oncologist turned biotech entrepreneur whose company building spreefrom Agensys and Cougar to Kite Pharmahelped usher in the first FDA approved CAR T therapy and led to Kites $11.9 billion sale to Gilead Sciences.After that landmark exit, he co-founded Allogene Therapeutics and still serves as its Executive Chairman, steering the next wave of off the shelf (allogeneic) CAR T cell products toward the clinic.Beyond Allogene, Belldegrun deploys capital through Bellco Capital, Two River, Symbiotic Capital, Vida Ventures, and the real estate venture Breakthrough Properties, nurturing a constellation of startups that translate science into patient impact.Over three decades on UCLAs faculty, he has authored 500 plus scientific papers, mentored a generation of physician scientists, and kept patient benefit at the center of every dealcementing his reputation as one of precision medicines most influential builders.